A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

H. L.Y. Chan, D. Messinger, G. V. Papatheodoridis, M. Cornberg, Q. Xie, T. Piratvisuth, H. Ren, P. T. Kennedy, A. Thompson, A. Caputo, G. Bakalos, V. Pavlovic, P. Lampertico

Research output: Contribution to journalArticle

Abstract

Background: Peginterferon induces off-treatment responses in approximately one-third of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Aim: To develop an easy-to-use baseline prediction score to identify hepatitis B virus (HBV) genotype B-/C-infected HBeAg-positive Asian patients likely to respond to peginterferon alfa-2a. Methods: Generalised additive models, multiple logistic regression (MLR) analysis and internal validation methods were applied to data from 647 HBeAg-positive patients from China, Hong Kong and Taiwan to develop a scoring system to predict response 24 weeks after completing a 48-week course of peginterferon alfa-2a. Results: Five baseline factors (age, sex, alanine aminotransferase ratio, hepatitis B surface antigen (HBsAg) level and HBV DNA level) were retained in the final MLR for HBeAg seroconversion and used to develop a scoring system from 0 to 7. Among patients with scores of 0-1, 2-3, 4 or ≥5, HBeAg seroconversion was achieved in 6.4% (6/94), 23.0% (61/265), 36.4% (67/184) and 54.8% (57/104), respectively, and a combined response (HBeAg seroconversion plus HBV DNA <2000 IU/mL) in 5.3% (5/94), 12.8% (34/265), 25.0% (46/184) and 36.5% (38/104), respectively. Among patients with scores of 0-1, 2-3, 4 or ≥5, 57.0% (53/93), 12.3% (31/253), 3.4% (6/178) and 1.0% (1/100) had HBsAg ≥20 000 IU/mL at treatment Week 12; only 3/91 (3.3%) with HBsAg ≥20 000 IU/mL experienced a combined response at 24 weeks post-treatment (negative predictive value = 97% [88/91]). Conclusion: A pre-treatment scoring system using readily available baseline characteristics identifies HBeAg-positive Asian patients likely to experience sustained HBeAg seroconversion after treatment with peginterferon alfa-2a.

Original languageEnglish
Pages (from-to)547-555
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume48
Issue number5
DOIs
Publication statusPublished - Sep 1 2018

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B'. Together they form a unique fingerprint.

  • Cite this

    Chan, H. L. Y., Messinger, D., Papatheodoridis, G. V., Cornberg, M., Xie, Q., Piratvisuth, T., Ren, H., Kennedy, P. T., Thompson, A., Caputo, A., Bakalos, G., Pavlovic, V., & Lampertico, P. (2018). A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 48(5), 547-555. https://doi.org/10.1111/apt.14862